CurrentUnitedHealthcarePolicy MP.012.22

Mastectomy for Gynecomastia

Defines medical necessity criteria, clinical background, and coding for mastectomy to treat gynecomastia for UnitedHealthcare Commercial and Individual Exchange members.

Policy Summary

PayerUnitedHealthcare

PolicyMastectomy for Gynecomastia

Policy CodePolicy MP.012.22

Change TypeClarified clinical evidence and references

Effective DateJun 1, 2026

Next Review Date

Key ActionObtain prior authorization for CPT 19300 with documentation supporting grade, duration, and prior conservative management per policy criteria.

SourceLink

POLICY UPDATE CHANGES

Updated Clinical Evidence and References sections to reflect the most current information; previous policy version MP.012.21 archived.

19300Primary procedure code listed

Grade II-IVGrades specified

≥2 yrsPediatric duration

3.9% / 1.9%30-day complication rates

Coverage Criteria for Mastectomy to Treat Gynecomastia

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medical Necessity Criteria — Age-specific

Covered when ALL of the following are met:

Pediatric (under 18): Gynecomastia stage II, III, or IV with moderate to severe chest pain causing a Functional or Physical Impairment (inability to participate in sports or social activities alone does not qualify); glandular breast tissue is the primary cause (not pseudogynecomastia) documented on physical exam and/or mammography; persistent after cessation of prescribed medications, nutritional supplements, and appropriate screening of nonprescription and/or recreational drugs known to cause gynecomastia; present for at least 2 years; appropriate evaluation of medical causes with normal supporting laboratory testing (examples: β‑hCG, thyroid function studies, sex hormone‑binding globulin, estradiol, FSH, LH, prolactin, testosterone, liver enzymes, serum creatinine, α‑fetoprotein).all conditions required

Per policy text

Adult (18 and over): Gynecomastia stage II, III, or IV with moderate to severe chest pain causing a Functional or Physical Impairment (inability to participate in sports or social activities alone does not qualify); glandular breast tissue is the primary cause (not pseudogynecomastia) documented on physical exam and/or mammography; persistent after cessation of prescribed medications, nutritional supplements, and appropriate screening of nonprescription and/or recreational drugs known to cause gynecomastia; appropriate evaluation of medical causes with normal supporting laboratory testing (examples: β‑hCG, thyroid function studies, sex hormone‑binding globulin, estradiol, FSH, LH, prolactin, testosterone, liver enzymes, serum creatinine, α‑fetoprotein).all conditions required

Per policy text

Initial surgical coverage criteria

Covered when ALL of the following are met:

Severity and persistence: Gynecomastia meets specified grade and timing thresholds: adolescents — unilateral or bilateral grade II or III persistent >1 year after pathological causes ruled out or >6 months after failed medical therapy; grade IV persistent >6 months after pathological causes ruled out or >6 months after failed medical therapy; adults — unilateral or bilateral grade III or IV persistent >3–4 months after pathological causes ruled out or after failed medical therapy.see ASPS grading and timeframes

ASPS 2016 recommendations

Diagnostic evaluation: Clinical evaluation documented to exclude underlying pathology including medication/substance history, genital/testicular examination and imaging as indicated, and breast exam confirming palpable glandular tissue (or breast biopsy if malignancy suspected); relevant laboratory testing as indicated (e.g., hormones, liver/renal markers, α‑fetoprotein).as per ASA/EAA and ASPS recommendations

Includes screening to differentiate lipomastia (pseudogynecomastia)

Conservative management: Appropriate watchful waiting and/or medical therapy performed and documented where indicated (including cessation of causative agents); surgery reserved for persistent gynecomastia that does not regress after addressing underlying causes or failed medical therapy.timing per ASPS and ASA/EAA guidance

ASA/EAA recommend watchful waiting after addressing causes; selective agents generally not recommended

Benefit coverage for gynecomastia procedures varies by plan. Most benefit plans explicitly exclude coverage for treatment of benign gynecomastia; however, some states or member-specific benefit plans may require or allow coverage. Always refer to the member-specific benefit plan document to determine whether the mastectomy for gynecomastia is covered for a given member, and confirm any prior authorization requirements for CPT 19300 when applicable.

Differentiate true gynecomastia from pseudogynecomastia (lipomastia): true gynecomastia is driven by glandular breast tissue and should be documented on physical examination and/or mammography. If the enlargement is due primarily to fatty tissue (pseudogynecomastia), surgical mastectomy for glandular removal is not indicated. The ASA/EAA guidance also recommends initial screening to rule out lipomastia and emphasizes documenting palpable glandular tissue to distinguish the two entities before considering surgery.

Cases that do not meet the policy’s medical necessity criteria are not eligible for surgical coverage. Examples include pseudogynecomastia (breast enlargement primarily from fat rather than glandular tissue), gynecomastia of insufficient duration (e.g., pediatric cases present 2 years), lack of documented Functional or Physical Impairment, or gynecomastia expected to resolve after cessation of a causative medication or substance. Documentation must confirm glandular tissue, duration, and persistence after addressing reversible causes.

Before surgical intervention, conservative measures should be considered and documented. These include discontinuation of medications or substances known to cause gynecomastia and appropriate watchful waiting. Pharmacologic therapies (for example, selective estrogen receptor modulators such as tamoxifen) may be considered in selected cases, but the ASA/EAA guidance states that the routine use of selective estrogen receptor modulators, aromatase inhibitors, or nonaromatizable androgens for general treatment of gynecomastia is not recommended. Surgery is reserved for persistent gynecomastia after correction of underlying causes or failed medical/observational management.

Coding and Procedural Codes

Applicable CPT CodesCPTCovered

19300

Mastectomy for gynecomastia

Regulatory / informationalmixed

No codes listed

inv-09: Duration of gynecomastia

Pediatric duration requirementGynecomastia must be present for at least 2 years for individuals under age 18.

Medication/substance correctionPersistence must be after cessation of prescribed medications, supplements, and screening for nonprescription/recreational drugs known to cause gynecomastia.

DocumentationDuration must be documented in the medical record as part of required clinical documentation for prior authorization and medical necessity review.

Provider Requirements and Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for mastectomy for gynecomastia (CPT 19300). Documentation must demonstrate that criteria for medical necessity are met, including severity, duration, failure of conservative/medical therapy where applicable, and exclusion of underlying pathology.

Prior authorization required for CPT 19300 (mastectomy for gynecomastia).
Provide documentation of severity (grade) and persistence/duration.
Document prior medical therapies attempted and response, and that causative medications/substances were discontinued when applicable.
Provide evaluation and testing to exclude underlying pathology (imaging, labs, biopsy when indicated).

Denial Risk

Benefit Exclusion / Insufficient Documentation

Clinical documentation may be requested to determine whether the member meets the policy criteria. Insufficient or missing documentation, or a member-specific benefit exclusion for treatment of benign gynecomastia, may result in denial or non-coverage.

If the member's benefit plan excludes treatment of benign gynecomastia, services may be denied regardless of clinical findings.
Medical records (progress notes, exam findings, imaging, lab results, medication history) may be required to substantiate medical necessity.

Documentation Required

Documentation of Severity and Persistence

Claims and prior authorization requests must document the clinical grade and persistence of gynecomastia. For adults, document Grade III or IV disease; for adolescents, document Grade II–IV as applicable. Include how long gynecomastia has been present and whether it persisted after appropriate intervals of observation and therapy.

Document grade (use ASPS/ASPS-adapted grading: Grade II, III, IV).
Adults: document Grade III or IV.
Adolescents: document Grade II or higher when meeting other criteria.
Document duration (e.g., adolescents: >1 year after pathology ruled out for Grade II/III; >6 months for Grade IV; adults: persistent for 3–4 months after pathology ruled out per ASPS guidance; policy also references 2 years in some pediatric criteria).
Document persistence after cessation of causative agents and after appropriate trial of medical therapy where recommended.

Documentation Required

Required Clinical Documentation

Provide comprehensive clinical documentation with the prior authorization or claim to support medical necessity. Include history, physical exam findings confirming palpable glandular tissue (to distinguish from pseudogynecomastia), medication/substance history, details of prior conservative or medical treatments, imaging and laboratory results, and consultations or specialist evaluations when performed.

History: onset, duration, sexual development/function, substance/medication exposure.
Physical exam: presence of palpable glandular tissue, signs of systemic disease, genital exam/testicular evaluation when indicated.
Imaging: breast ultrasound and/or mammogram if malignancy suspected or exam equivocal.
Laboratory testing: hormone panel (testosterone, estradiol, LH, FSH, prolactin, hCG), thyroid studies, liver enzymes, creatinine, α-fetoprotein when indicated.
Biopsy: core-needle biopsy if malignancy suspected.
Medication reconciliation showing discontinuation of causative agents when applicable.

Note

Conservative Management / Medical Therapy

Conservative and medical management should be attempted or considered before surgery when clinically appropriate. This includes discontinuation of causative medications/substances, treatment of underlying conditions, and consideration of medical therapies in selected patients (for example, tamoxifen for drug-induced gynecomastia), consistent with guideline recommendations. Document duration and response to these measures.

Discontinue medications/supplements/substances known to cause gynecomastia and document an observation period.
Consider and document trials of medical therapy (e.g., selective estrogen receptor modulators such as tamoxifen) when indicated and report duration and outcome.
Treat underlying medical conditions (e.g., hypogonadism, liver disease) prior to surgery when applicable.
Document counseling and shared decision-making regarding risks/benefits of medical vs surgical management.

Prior Authorization

Conservative Management Before Surgery

Non-surgical options and watchful waiting are recommended initially. Surgery is typically reserved for persistent gynecomastia that does not resolve after cessation of causative agents, treatment of underlying pathology, and an adequate trial of medical therapy when indicated. Ensure documentation shows conservative measures were tried for the recommended observation periods per age and grade before approving surgery.

Adolescents: follow ASPS timelines (e.g., Grade II/III: continue >1 year after pathology ruled out and after ≥6 months failed medical therapy; Grade IV: continue >6 months after pathology ruled out and after ≥6 months failed medical therapy).
Adults: document persistence for 3–4 months after pathological causes ruled out and after 3–4 months of failed medical therapy for Grade III/IV per ASPS guidance (some pediatric-specific criteria reference longer durations).
If tumor/neoplasm is suspected at any age, perform appropriate imaging and further management prior to watchful waiting or surgery.

Clinical Background

Gynecomastia is a benign proliferation of glandular breast tissue in males with physiologic peaks in newborns, adolescents, and older men. Clinical presentation varies by age and severity; grading scales such as the ASPS Gynecomastia scale (Grades II–IV) are used to classify enlargement and guide treatment decisions. Management includes evaluating and treating underlying causes (medications, systemic disease, tumors), considering conservative or medical therapy when appropriate, and offering surgical removal of glandular tissue when the policy’s criteria for persistent, symptomatic, glandular gynecomastia are met.

Definitions and Grading

inv-19: Definition — Functional or Physical Impairment

DefinitionA deviation from normal function of a tissue or organ resulting in significantly limited capacity to move, coordinate actions, or perform physical activities and basic life functions.

Clinical examplesMay be exhibited by difficulties with physical/motor tasks, independent movement, or performing basic life functions; inability to participate in sports/social activities alone is not considered impairment under this policy.

Use in criteriaFunctional or Physical Impairment is required to document moderate to severe chest pain or impairment for medical necessity of reconstructive mastectomy in adolescents and adults.

inv-20: Definition — Gynecomastia (benign glandular breast tissue proliferation in males)

Basic definitionBreast enlargement in boys or men due to a benign (noncancerous) increase in breast glandular tissue.

Etiology to considerPhysiologic peaks occur in newborns, adolescents, and older men; nonphysiologic causes include medications, systemic disease, and tumors — evaluation required.

Clinical distinctionPolicy requires glandular tissue to be the primary cause (not fatty deposits) documented on exam and/or mammography for surgical coverage.

inv-21: ASPS Gynecomastia scale Grades II-IV

Grade IIModerate breast enlargement exceeding areola boundaries, with edges indistinct from the chest.

Grade IIIModerate enlargement exceeding areola boundaries with skin redundancy present (edges indistinct from the chest).

Grade IVMarked breast enlargement with skin redundancy and feminization of the breast.

inv-22: pseudogynecomastia (lipomastia) — Differentiate fat-only enlargement from true gynecomastia

DefinitionPseudogynecomastia (lipomastia) is breast enlargement due primarily to excess fatty tissue without palpable glandular proliferation.

AssessmentDifferentiate from true gynecomastia by physical exam (palpable glandular tissue) and breast imaging when clinical exam is uncertain.

Coverage implicationCases due solely to pseudogynecomastia do not meet policy criteria for mastectomy unless glandular tissue is documented.

inv-23: Gynecomastia grading (ASPS/modified McKinney/Simon/Hoffman/Kohn) — Clinical grading scales referenced

Referenced scalesPolicy references ASPS grading and modified McKinney/Simon, Hoffman, and Kohn scales to categorize severity (grades II–IV) used to guide surgical indications and timing.

Adolescent timing (ASPS 2016)Grade II–III: continues >1 year after pathological causes ruled out or >6 months after failed medical treatment; Grade IV: continues >6 months after causes ruled out or after failed medical treatment.

Adult timing (ASPS 2016)Grade III–IV: continues >3–4 months after pathological causes ruled out or >3–4 months after failed medical therapy; biopsy if malignancy suspected.